US stock futures flat after Wall St drops on Trump tariffs, soft jobs data
Rutledge Napoleon B. Jr., the Senior Vice President, Controller, and Chief Accounting Officer of McKesson Corp (NYSE:MCK), a healthcare services giant with a market capitalization of $89.9 billion and an impressive YTD return of 26%, has recently executed a significant stock sale. According to a Form 4 filing with the Securities and Exchange Commission, Napoleon sold 543 shares of McKesson’s common stock on May 19, 2025. The shares were sold at a price of $726.51 per share, resulting in a total transaction value of $394,494. The sale occurred as the stock trades near its 52-week high of $731, with InvestingPro analysis indicating the stock is currently fairly valued. This sale was made under a pre-established trading plan dated February 7, 2025, in compliance with Rule 10b5-1(c).
Following this transaction, Napoleon’s direct ownership of McKesson’s common stock stands at 1,972 shares.
Additionally, on May 20, 2025, Napoleon acquired 223 Restricted Stock Units (RSUs) at no cost. These RSUs will vest in three equal installments on May 20 of each year from 2026 to 2028. This acquisition brings his total RSU holdings to 223 shares.
In other recent news, McKesson Corporation reported a strong fiscal fourth quarter, with earnings per share (EPS) exceeding Wall Street expectations by 3%. The company provided an optimistic EPS guidance for fiscal year 2026, which is above current analyst projections. McKesson’s management has maintained a long-term EPS growth outlook of 12% to 14% and increased the operating income growth projection for its U.S. Pharmaceutical (TADAWUL:2070) segment to between 6% and 8%. Jefferies analyst Rob Dickerson raised the price target for McKesson shares to $800, maintaining a Buy rating due to the company’s robust performance and appealing valuation.
Additionally, McKesson reported a Q3 2025 adjusted EPS of $10.12, surpassing the forecast of $9.81, although revenue fell short of expectations at $90.82 billion against a forecast of $93.48 billion. The company achieved a 20% year-over-year growth in EPS and announced plans to separate its Medical (TASE:BLWV) Surgical segment into an independent entity. McKesson’s strategic acquisitions, including interests in Prism Vision and pending acquisitions in CORE Ventures, have bolstered its position in the healthcare services sector. Looking ahead, McKesson projects revenue growth of 11% to 15% for fiscal 2026, with an anticipated EPS range of $36.05 to $37.55.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.